Conor faces litigation from Boston and Angiotech
This article was originally published in Clinica
Executive Summary
Boston Scientific and Angiotech Pharmaceuticals, the Canadian company from which Boston exclusively licenses its paclitaxel stent-coating technology, have filed a joint lawsuit against Conor Medsystems in the Netherlands. Vancouver-based Angiotech launched the legal action against Menlo Park, California-based Conor after obtaining a favourable decision on its European patent No 0706,376 on January 24.